前哨淋巴结活检与择区性颈清扫在cT1-2N0口腔癌中的比较
该研究通过系统评价与荟萃分析比较了前哨淋巴结活检(SNB)与择区性颈清扫(END)在cT1-2N0口腔鳞状细胞癌手术中的总生存(OS)和无病生存(DFS)。纳入10项研究共10498例患者,结果显示两组OS和DFS均无显著差异,提示SNB可能作为END的替代选择。
要点
- SNB与END在cT1-2N0口腔癌患者中OS和DFS无显著差异。
- SNB可能作为早期临床淋巴结阴性口腔癌的替代管理策略。
- 纳入研究异质性在DFS分析中存在,需谨慎解读。
核心结论
- 在cT1-2N0口腔鳞状细胞癌中,SNB与END的总生存和无病生存无统计学显著差异。
- SNB可能是早期临床淋巴结阴性口腔癌管理中END的替代方案。
研究设计与样本
- 系统评价与荟萃分析,检索PubMed和Embase(2021年5月9日)。
- 纳入10项研究:5项回顾性、3项前瞻性、2项随机对照试验,共10498例患者(END 9102例,SNB 1396例)。
主要发现
- 总生存(OS):HR=0.92(95%CI 0.65-1.31),无显著差异。
- 无病生存(DFS):HR=0.70(95%CI 0.41-1.20),无显著差异。
- OS合并分析未检测到异质性(P=.18;I2=30%),DFS合并分析存在异质性(P=.003;I2=66%)。
关键数值与推荐
- 纳入标准:比较SNB与END在cT1-T2N0 OCSCC患者中的研究,报告HR、Kaplan-Meier曲线或P值及事件数,研究类型为临床试验、队列或病例对照研究。
- 使用PRISMA指南、ROBINS-I工具和修订版Cochrane随机试验偏倚风险工具进行质量评价。
- 采用通用逆方差法和随机效应模型进行荟萃分析。
临床怎么用
- 对于cT1-2N0口腔鳞状细胞癌,SNB可作为END的替代选择,尤其适用于希望避免颈清扫并发症的患者。
- 临床决策应结合患者具体情况和多学科评估,考虑SNB的可行性和随访条件。
局限性
- 纳入研究以回顾性为主(5项回顾性、3项前瞻性、2项随机对照试验),可能存在选择偏倚。
- DFS合并分析存在显著异质性(I2=66%),可能影响结果稳定性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare overall survival (OS) and disease-free survival (DFS) between sentinel lymph node biopsy (SNB) and elective neck dissection (END) in the surgical management of cT1-2N0 oral cavity squamous cell carcinoma (OCSCC). METHODS: English full-text articles were searched in PubMed and Embase on May 9, 2021. Articles had to compare SNB with END in cT1-T2N0 OCSCC patients; report hazard ratios (HRs), Kaplan-Meier curves, or P-values with total number of events for survival outcomes; be from a clinical trial, cohort, or case-control study. Two reviewers reviewed articles and a third settled disagreements. Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and the Risk of Bias in Non-randomized Studies of Interventions tool and revised Cochrane risk-of-bias tool for randomized trials were used. The generic inverse variance method with a random-effect model was used for meta-analysis. RESULTS: Ten studies, five retrospective, three prospective, and two randomized controlled trials, were included (total number of patients [n] = 10,498, END n = 9102, SNB n = 1396). No significant differences were found in OS (HR = 0.92; 95% confidence interval [CI]: 0.65-1.31) or DFS (HR = 0.70; 95% CI: 0.41-1.20). Heterogeneity was not detected in pooled OS analysis (P = .18; I2 = 30%), but was in pooled DFS analysis (P = .003; I2 = 66%). CONCLUSIONS: No statistically significant differences in OS or DFS were observed between SNB and END in cT1-2N0 OCSCC, suggesting that SNB might be an alternative to END in the management of early-stage, clinically node-negative OCSCC. Laryngoscope, 132:989-998, 2022.
引用
- Saleem MI, Peng T, Zhu D, et al. Sentinel Lymph Node Biopsy Versus Elective Node Dissection in Stage cT1-2N0 Oral Cavity Cancer. Laryngoscope. 2021. PMID: 34637145. doi:10.1002/lary.29895
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。